Vivoryon Therapeutics Statistics

Total Valuation

Vivoryon Therapeutics has a market cap or net worth of GBP 44.75 million. The enterprise value is 31.84 million.

Market Cap	44.75M
Enterprise Value	31.84M

Important Dates

The next estimated earnings date is Thursday, April 24, 2025.

Earnings Date	Apr 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+3.35%
Shares Change (QoQ)	+6.30%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	21.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	4.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.20
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.58

Financial Position

The company has a current ratio of 9.37, with a Debt / Equity ratio of 0.00.

Current Ratio	9.37
Quick Ratio	9.12
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.00
Interest Coverage	-602.96

Financial Efficiency

Return on equity (ROE) is -112.35% and return on invested capital (ROIC) is -70.48%.

Return on Equity (ROE)	-112.35%
Return on Assets (ROA)	-62.86%
Return on Capital (ROIC)	-70.48%
Revenue Per Employee	-204,607
Profits Per Employee	-1.76M
Employee Count	15
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -73.85% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-73.85%
50-Day Moving Average	2.00
200-Day Moving Average	1.96
Relative Strength Index (RSI)	52.19
Average Volume (20 Days)	637

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Vivoryon Therapeutics had revenue of GBP -3.07 million and -26.44 million in losses. Loss per share was -1.05.

Revenue	-3.07M
Gross Profit	-2.62M
Operating Income	-26.58M
Pretax Income	-26.60M
Net Income	-26.44M
EBITDA	-26.51M
EBIT	-26.58M
Loss Per Share	-1.05

Full Income Statement

Balance Sheet

The company has 12.95 million in cash and 8,478 in debt, giving a net cash position of 12.94 million.

Cash & Cash Equivalents	12.95M
Total Debt	8,478
Net Cash	12.94M
Net Cash Per Share	n/a
Equity (Book Value)	11.85M
Book Value Per Share	0.45
Working Capital	12.15M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.34 million and capital expenditures -4,239, giving a free cash flow of -12.35 million.

Operating Cash Flow	-12.34M
Capital Expenditures	-4,239
Free Cash Flow	-12.35M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	866.13%
Pretax Margin	866.69%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vivoryon Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.35%
Shareholder Yield	-3.35%
Earnings Yield	-59.08%
FCF Yield	-27.59%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Vivoryon Therapeutics has an Altman Z-Score of 18.09.

Altman Z-Score	18.09
Piotroski F-Score	n/a